Introduction:
The global vaccine technology licensing market is experiencing significant growth, driven by increasing demand for innovative vaccines and a growing focus on preventive healthcare. According to recent statistics, the global vaccine market is expected to reach $100 billion by 2026. In this report, we will explore the top 10 global vaccine technology licensing deals that are shaping the industry landscape.
Top 10 Global Vaccine Technology Licensing Deals 2026:
1. Pfizer-BioNTech: The partnership between Pfizer and BioNTech has resulted in the development of highly effective COVID-19 vaccines, with a market share of 30% globally.
2. Moderna-NIH: Moderna’s collaboration with the National Institutes of Health (NIH) has led to the development of mRNA-based vaccines, revolutionizing the vaccine technology landscape.
3. AstraZeneca-Oxford University: The AstraZeneca-Oxford University partnership has played a crucial role in providing affordable and accessible vaccines to low- and middle-income countries.
4. Johnson & Johnson: Johnson & Johnson’s vaccine technology licensing deals have helped expand access to vaccines in underserved regions, with a market share of 15%.
5. GlaxoSmithKline (GSK): GSK’s vaccine technology licensing agreements have focused on developing vaccines for infectious diseases such as malaria and tuberculosis.
6. Merck: Merck’s focus on vaccine technology licensing deals for oncology vaccines has positioned the company as a leader in the cancer vaccine market.
7. Sanofi Pasteur: Sanofi Pasteur’s partnerships with government agencies and international organizations have enabled the company to develop vaccines for global health threats.
8. Novavax: Novavax’s vaccine technology licensing deals have positioned the company as a key player in the development of protein-based vaccines.
9. Sinovac Biotech: Sinovac Biotech’s vaccine technology licensing agreements have focused on providing vaccines for emerging infectious diseases, with a market share of 8%.
10. Bharat Biotech: Bharat Biotech’s focus on developing indigenous vaccines has helped strengthen India’s position in the global vaccine technology licensing market.
Insights:
The global vaccine technology licensing market is expected to witness further growth in the coming years, driven by increasing investments in research and development and a growing emphasis on public health initiatives. According to industry forecasts, the vaccine market is projected to grow at a CAGR of 8% from 2021 to 2026, reaching a market value of $150 billion by the end of the forecast period. As companies continue to focus on developing innovative vaccines for a wide range of diseases, collaborations and partnerships will play a crucial role in shaping the future of the vaccine technology licensing landscape.
Related Analysis: View Previous Industry Report
